Novo expects GLP-1 products to drive diabetes business growth
Drugs like Rybelsus and Ozempic are predicted to have the most impact on the growth of Novo Nordisk’s diabetes treatments, the company reveals on its capital markets day.
by marketwire, translated by catherine brett
Novo Nordisk now has a 30.3 percent share of the diabetes market, and is well on the way to achieving its long-term goal of controlling a third of the market. In 2019, the company’s market share was 28 percent.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Wegovy update on Novo Nordisk's capital markets day agenda
For subscribers
